Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Executive Summary

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

You may also be interested in...



Generic Drug Approvals Still Winning The Pandemic At US FDA

Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.

Generic Drug Approvals Still Winning The Pandemic At US FDA

Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.

The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence

Applications for US FDA approval are lower than in recent history, portending a lean 2021.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel